A clinical update in polycythemia vera and essential thrombocythemia-Reference-Cited by-同舟云学术

A clinical update in polycythemia vera and essential thrombocythemia

Published:2000-08 Issue:2 Volume:109 Page:141-149
ISSN:0002-9343
Container-title:The American Journal of Medicine
language:en
Short-container-title:The American Journal of Medicine

Author:

Tefferi Ayalew,Solberg Lawrence A,Silverstein Murray N

Publisher

Elsevier BV

Subject

General Medicine

Reference97 articles.

1. Life expectancy of patients with chronic nonleukemia myeloproliferative disorders;Rozman;Cancer,1991

2. Bleeding and thrombosis in the myeloproliferative disorders;Schafer;Blood,1984

3. Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD. Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group. In: Wasserman LR, Berk PD, Berlin NI, eds. Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia: WB Saunders; 1995:166–194.

4. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis;Cortelazzo;N Engl J Med,1995

5. Clonal development of myeloproliferative disorders;Raskind;Leukemia,1998

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thrombosis of Coronary Arteries in a Patient With Polycythemia Vera During the Myocardial Revascularization: A Case Report;International Surgery;2021-01-01

2. The JAK2 mutation;Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part A;2021

3. Comparison of starting doses of anagrelide as a first-line therapy in patients with cytoreductive therapy-naïve essential thrombocythemia: difference between starting at 0.5 and 1.0 mg/day;International Journal of Hematology;2020-04-23

4. ERYTHROCYTOSES IN PATIENTS WITH DILATED AND ISHAEMIC CARDIOMYOPATHY;Russian Clinical Laboratory Diagnostics;2020-04-15

5. Evaluation of the JAK2 V617F gene mutation in myeloproliferative neoplasms cases: a one-center study from Eastern Anatolia;Turkish Journal of Biochemistry;2019-02-14